Investigator(s)
| WHO Technical Officer |
Mohammad Ahmad WCO India- Research Mohammad Ahmad 
|
| Principal Investigator |
Shailesh Pawar Indian Council of Medical Research -National Institute of Virology (ICMR-NIV, Pune) Shailesh Pawar
|
Title(s) and abstract
| Scientific title | ‘Cross-Sectional Serologic Assessment of Immunity toPolioviruses and Measles-Rubella in Different Risk States of India |
| Public title | India Seroprevalence Study - 2023 |
| Background | Since the launch of the Global Polio Eradication Initiative (GPEI) in 1988, five of the six World Health Organization (WHO) regions have been certified wild poliovirus free. The GPEI Endgame Strategic Plan (2022-2026) outlined to strengthen plans to achieve and sustain polio-free world. To mitigate the risks associated with WPV importations and emergence of cVDPVs, India continues its efforts to raise population immunity and conducted regular serosurveys during 2007-2019 to assess the population immunity against polioviruses in the high-risk areas. The results from study 2019 show overall seroprevalence of 98%, 47% and 95% for types 1,2 & 3 respectively. The 30th Meeting of the India Expert Advisory Group (2022) on polio eradication and 5th IEAG meeting on measles and rubella (MR) elimination (June 2023) have recommended that polio and MR seroprevalence study be conducted in India as soon as possible to understand the immunity gaps. Keeping in view of the IEAG recommendation and to guide the polio endgame and MR elimination, WHO India in collaboration with partners, proposes to conduct a polio and MR seroprevalence study in selected high-risk states/area, among the children |
| Objectives | Primary Objective: 1. To assess the seroprevalence against type-2 poliovirus in selected high-risk states/area in India, among children 6-35 months stratified into 6-11 months, 18-23 months and 30-35 months of age Secondary objectives: 1. To understand the IgG antibody response against MR vaccination in the routine immunization schedule as a nested study 2. To assess the seroprevalence against types 1 & 3 polioviruses in the studied age groups 3.To compare seroprevalence between different study states 4.To analyse vaccine (bOPV-IPV / MR) dose/response relationship to polio and MR seroprevalence |
| Study Methods | The study is designed to be a cross-sectional seroprevalence study of neutralizing antibodies against all three poliovirus types and IgG antibody for measles and rubella virus, among children in the study ages residing in selected high- risk states. A total of 1440 children will be enrolled for one time visit to health facilities four study states (Uttar Pradesh, Assam, Rajasthan and Maharashtra). Five districts will be selected for the study from each state. Six children will be enrolled from each of the 12 clusters in the study district. These six children would be divided into two each from age groups of 6-11, 18-23, and 30-35 months. This arrangement will provide 72 subjects in each block/ward; giving a sample size of 360 subjects in each state (6 children in each cluster X 12 clusters in each district X 5 districts in each study state). An informed signed consent will be obtained from participating parents. A health facility (PHC/CHC etc. or any other government facility) will be set up as study site for blood collection and processing. At the health facility, a study physician will administer a short questionnaire and carry out a physical examination of the child and thereafter collect blood sample. |
| Expected outcomes and use of results | 1- Seroprevalence against polio in the high-risk states of India 2- Seroprevalence against measles and rubella in the high-risk states of India 3- Infor the results to India Expert Advisory Group (IEAG) Polio & MR for policy decisions |
| Keywords | Seroprevalence India 2023 Polio MR |
Research Details
| Student research | No |
| Start Date | 01-Nov-2023 |
| End Date | 31-Dec-2023 |
| Key Implementing Institution | WCO India |
| Multi-country research | No |
| Nationwide research | Yes |
| Research Domain(s) | Communicable Disease Research |
| Research field(s) | Immunization/Vaccine Preventable Disease |
| Involves human subjects | Yes |
| Population-Based Survey | |
| Data Collection | Primary data |
| Proposal reviewed by other Committee | Under Review |